1	Thomas W. McNamara		
2	info@regulatoryresolutions.com Regulatory Resolutions 655 West Broadway, Suite 1600		
3	San Diego, California 92101 Telephone: 619-269-0400		
4	Facsimile: 619-269-0401		
5	Court-Appointed Receiver		
6	Andrew W. Robertson (SBN 62541)		
7	arobertson@mcnamarallp.com Edward Chang (SBN 268204) echang@mcnamarallp.com		
8	McNamara Smith LLP 655 West Broadway, Suite 1600		
9	San Diego, California 92101 Telephone: 619-269-0400		
10	Facsimile: 619-269-0401		
11	Attorneys for Receiver		
12	UNITED STATES DISTRICT COURT		
13	CENTRAL DISTRICT OF CALIFORNIA		
14	SECURITIES AND EXCHANGE COMMISSION,	Case No. 2:16-cv-02594-TJH (FFMx)	
15	Plaintiff,		ER'S FOURTH STATUS AND ACCOUNTING
16	v.	Judge:	Hon. Terry J. Hatter, Jr.
17	PLCMGMT LLC, dba PROMETHEUS	Ctrm.:	9B
18	LAW, JAMES A. CATIPAY, and DAVID A. ALDRICH,		
19	Defendants.		
20			
21			
22			
23			
24			
25			
26			
27			
28			

TABLE OF CONTENTS Page II. Receivership Accounting1 В. Sales Agents......2 2. Prometheus Capital Partners 3 3. Catipay's Friends and Family 3 Case Portfolio 3 C.

RECEIVER'S FOURTH STATUS REPORT AND ACCOUNTING

As the Court-appointed Receiver of Defendant PLCMGMT LLC, dba Prometheus Law ("Prometheus"), ¹ I submit this Fourth Status Report and Accounting.

I. First Interim Distribution

The recent sale of the Flower Street Condo has provided enough funds, combined with other assets, to commence interim distributions to investors. On December 12, 2017, we filed a motion with the Court for approval of "Procedures for the Final Determination of Investor Claims and Interim Distributions to Investors" and for approval of a first interim distribution of \$1,056,000 which is 9% of the overall investor losses (ECF No. 108). Upon approval, we will immediately commence implementation of the first interim distribution and the related procedures. Each of the 251 investors will receive a pro rata distribution equal to 9% of their net stripped capital loss.

The amount of funds ultimately available to investors through future interim distributions will be driven by the success of the Case Portfolio as to which the receivership has a claim to a portion of any fees paid to lead counsel from successful cases. *See* Section III.C *infra*.

II. Receivership Accounting

The receivership bank account currently has a cash balance of \$1,327,755. Attached as Exhibit A is the SEC Standardized Fund Accounting Report for the receivership period from appointment on April 26, 2016 through January 31, 2018. That reports indicates receipts of \$1,787,796, less disbursements of \$460,041, netting to cash of \$1,327,755. If the proposed interim distribution of \$1,056,000 is approved, net cash will be reduced to \$271,755.

¹ I was appointed by the Court's Preliminary Injunction entered April 26, 2016 (ECF No. 20).

III. Receivership Assets

A. Flower Street Condo in Los Angeles

We provided full details of the tangled history of this property (bought in 2015 with Prometheus funds) in the Third Status Report filed August 29, 2017 (ECF No. 99 at pages 2-3)

After clearing up the title and encumbrance issues, including removal of \$2.9 million Deed of Trust held by Prometheus Capital Partners ("PCP"), and making necessary repairs, we offered the property for sale. We identified a buyer and secured the court's approval to the terms of sale (Order entered November 13, 2017 (ECF No. 105)) At closing, net proceeds of \$968,993 were delivered to the receivership.

B. Clawback Claims

1. <u>Sales Agents</u>

To date, clawback claims against Prometheus sales agents have contributed \$310,439 to the receivership with another \$20,975 to be paid over time.

Settlement of the separate clawback action against PCP, described below, includes return of its \$119,000 commission over time

The clawback lawsuit against the 20 sales agents with whom we could not settle pre-litigation² is near conclusion. Eleven defendants settled, one was dismissed for improper venue, and the eight others defaulted, as to whom the Receiver will seek formal Default Judgments. One of the defaulting defendants, (commissions of \$320,250) filed for bankruptcy in Houston, Texas after service of the Complaint. We retained bankruptcy counsel in Texas and they were instrumental in having the bankruptcy petition dismissed. Other defaulting defendants include one agent (commissions of \$73,458) who resides in Mexico,

² McNamara v. Allen, et al., (C.D. Cal.) Case No. 2:17-cv-02858-TJH (FFMx).

and two agents (aggregate commissions of \$108,000) who have threatened to file bankruptcy.

2. <u>Prometheus Capital Partners</u>

By the settlement agreement dated August 18, 2017, we settled the lawsuit filed against PCP³ which included cancellation of the \$2.9 million Deed of Trust on the Flower Street Condo. This agreement cleared the way for the Receiver's sale of the Flower Street Condo, noted above.

3. <u>Catipay's Family and Friends</u>

The third clawback lawsuit,⁴ filed June 12, 2017, seeks recovery of approximately \$1.3 million disbursed to Catipay's family and friends (parents, sister, brother, ex-wife, and former girlfriend). Pursuit of these claims is problematic – we reached a modest settlement with Catipay's sister (\$21,112 to be paid over time), but Catipay's parents and ex-wife have filed for bankruptcy in Los Angeles County and his brother has defaulted. His former girlfriend filed an answer to the Complaint, but has otherwise ignored all court-directed obligations and failed to participate in the case. Most recently, she failed to oppose the Receiver's Motion for Summary Judgment. We have retained bankruptcy counsel to preserve the Receiver's claims in these bankruptcy cases.

C. Case Portfolio

The primary potential asset of the receivership remains the case portfolio of mass tort cases generated by Prometheus-funded marketing. But, there is limited certainty or predictability as to the ultimate value of that portfolio. The only real certainty is that the portfolio is not what Prometheus portrayed it to be:

24 ///

³ McNamara v. Prometheus Capital Partners, LLC, (C.D. Cal.) Case No. 2:17-cv-04821-TJH (FFMx).

⁴ McNamara v. Catipay, et al., (C.D. Cal.) Case No. 2:17-cv-04347-TJH (FFMx).

- Although presenting itself as a "litigation marketing company,"
 Prometheus spent only 27% of the funds raised from investors on actual marketing. Not all of that marketing was productive or cost-efficient.
 The end result is the current portfolio of 2,278 cases, dominated by Risperdal (97% of total).
- Prometheus claimed that its cases would be pre-settled and covered by a mass tort settlement hence, the only risk was when, not whether the portfolio would pay off. But, less than 3% of the Prometheus cases involve drugs subject to mass tort settlements. The other cases, primarily Risperdal, were not pre-settled and have not settled yet. Even mass tort settlements include some level of risk on recovery amount because the settlement fund will be allocated to plaintiffs based on their specific facts.
- As is common in mass tort litigation, not all cases in the portfolio have been filed in court many reflect plaintiffs whose cases may be filed in the future and/or included in a future mass tort settlement. The value of a specific case, filed or unfiled, will vary by its own specific facts and the applicable law.
- Prometheus/Catipay, and now the receivership, has an interest in the portfolio, but that interest is limited to 33 1/3% of net fees paid to lead counsel in successful cases. Under this formula, the Prometheus portfolio must generate more than \$90 million in settlements to cover net investor losses of \$11.7 million. To date, the receivership has received \$185,043 as its fee share on settlements of 18 non-Risperdal cases.

Marketing and Case Acquisition

The Prometheus Due Diligence packet submitted to investors described its management team as litigation marketing experts, even extolling David Aldrich's "surgeon-like skill to market, screen, and qualify plaintiffs in extremely large numbers." In reality, neither Aldrich or Catipay were experienced or experts.

By June, 2014, however, Prometheus had only a "fee interest" in six active cases (a flat \$7,500 per case, \$45,000 total) which it sold at the discounted price of \$16,000 in order to fund payments to two investors.⁷

After James Catipay joined the business as "associate counsel" in November, 2013, Aldrich still drove the marketing with leads now referred to law firm Paglialunga & Harris ("P&H"), in particular partner James Harris, as "lead counsel." From November, 2013 through mid-April 2014, Aldrich engineered the disbursal of approximately \$700,000 to various third party vendors.⁸

⁵ Deposition of David Aldrich, February 22, 2016. In recalling his performance prior to the April, 2014 decision to switch marketing to Jim Harris/JRT, Aldrich cited his "limited experience" that gave him the "impression that a retained plaintiff was going to make a settlement" (page 122), that he "got burned to the tune of \$175,000" by two vendors who were re-selling his leads (page 114), and that he was "really losing a lot in the beginning" because even after retainers were secured, there was a "high wash-out" after medical records were pulled (page 112).

⁶ This expenditure preceded Catipay's involvement and was derived from the initial group of investors (\$158,000 invested June-November, 2013).

⁷ In an effort to avoid any issues on fee splitting, Worley initially executed promissory notes payable to an investor when a case settled. These notes were later "re-documented" with Catipay/Prometheus as the referral attorney entitled to a flat fee of \$7,500 per case from the contingency fee paid upon resolution of the case.

⁸ One of those vendors was P&H, which also had expertise in case acquisition sometimes delivered via its marketing affiliate JRT. "Net" disbursements to P&H for marketing during this period were \$134,000, which it expended on media and internet advertising. The gross disbursement was

By mid-April, 2014, the pace of portfolio building was disappointing at best. In acknowledgement of these results and Harris' relative expertise, Aldrich designated Harris/JRT to manage marketing going forward. From April 17, 2014 through December 18, 2014, JRT was provided \$2,391,000⁹ of Prometheus funds which it then placed in marketing campaigns. The Receiver has requested an accounting from P&H/JRT on their expenditures of these funds. They have been cooperative, but the process has been protracted. We project completion by March 15, 2018.

In January, 2015, Prometheus made one final marketing disbursement with no return benefit to date – \$100,000 was disbursed to a new vendor (Flood Law Group) for a new campaign (SSRI) with a new referral attorney (The Hood Law Firm). This appeared to be a "test," unknowingly funded by Prometheus investors, to evaluate potential new partners for a future venture – that test did generate 17 leads, but only three proved to be qualified plaintiffs and none of those three have settled or been resolved to date.

Portfolio Composition and Status

Despite the limited allocation of funds to, and the uneven quality of, its marketing, Prometheus did ultimately assemble a case portfolio which is now managed by P&H as lead counsel. The current portfolio contains 2,278 cases relating to 11 different drugs.

56 cases relate to six drugs now covered by mass tort settlements. ¹⁰ The receivership has now received \$185,043 as its fee share on settlement payments

^{\$259,000,} but P&H transferred \$125,000 to JRT on April 17, 2014 after Aldrich designated JRT to manage marketing.

⁹ \$2.266m was disbursed directly from Prometheus, the other \$125,000 was transferred from P&H.

¹⁰ These 56 cases involve Nuvaring (birth control device, four cases); TVM (mesh for treatment of pelvic organ prolapse in women, 23 cases), Actos (oral diabetes medicine, 20 cases), Yaz (birth control device; three cases), Topomax (antipsychotic; one case), Tylenol (two cases), and Pradaxa (blood thinner, three

made on 18 of those cases. The remaining 38 cases are subject to settlement processing which, when competed, will generate more fees to the receivership.

The remainder of the portfolio is dominated by 2,204 Risperdal cases,¹¹ an antipsychotic alleged to cause male breast growth. None of these cases have been settled or resolved to date. Lead counsel has consistently advised that projections as to value and timeline are difficult and that he is limited by ethical rules on what he can report to the Receiver or investors on individual cases. His attorney-client relationship is with each plaintiff, not the Receiver or investors, and he must protect privileged or confidential information. Lead counsel has, however, provided general status information which is reported below.

The filed Risperdal cases ¹² have been consolidated with thousands of other Risperdal cases in L.A. County Superior Court assigned to a single judge. That judge has made no rulings in our cases, but has made rulings in other cases, mostly adverse to plaintiffs. ¹³ There have been verdicts, some substantial, in favor of Risperdal plaintiffs in other jurisdictions – such results do provide an indication of the drug company's potential liability, but are not directly binding on other cases which will depend on their own facts.

cases). Settlements have been processed in 18 of those cases (four Nuvaring; four TVM; 10 Actos).

Other than the 56 mass tort settlement cases and the 2,204 Risperdal cases, there are 18 other unsettled cases: SSRI (antidepressants prescribed to pregnant women leading to birth defects, 15 cases); IUD (birth control device, two cases); and Xarelto (blood thinner, one case).

As is common in mass tort litigation, not all cases in a portfolio are filed cases, but they may be filed later and/or included in a future mass tort settlement.

One Risperdal case went to trial in late 2017, resulting in a defense verdict; the judge selected five Risperdal cases to be prepared for trial, but then granted motions for summary judgment filed by all five of them; the judge dismissed some Risperdal cases on the ground of federal pre-emption that federal law governed and hence the case could not be brought in state court, but that ruling has been appealed to the California Court of Appeal.

Lead counsel also cautions that Risperdal cases can be difficult to value: 1 2 plaintiffs have been prescribed antipsychotic medicine, hence they can be difficult clients; each case varies by its specific facts, including plaintiff's age, period and 3 extent of use, and medical records which document injury and usage; and 4 defendant may raise legal defenses, including statute of limitations and federal pre-5 emption. Even if there is a Risperdal mass tort settlement, recoveries for each 6 plaintiff will be determined by a settlement administrator, a process which can be 7 8 lengthy. 9 Investor questions coming into the Receiver's office have indicated some investor confusion and frustration about the case portfolio, in particular, the 10 absence of a projection on valuation and timeline. In an effort to address these 11 issues, we have posted on the Receiver's website a detailed "Case Portfolio FAQs" 12 13 which presents in one accessible place the available information regarding the case portfolio. 14 15 Dated: February 26, 2018 16 /s/ Thomas W. McNamara 17 Thomas W. McNamara. Receiver 18 19 20 21 22 23 24 25 26 27 28

CERTIFICATE OF SERVICE I hereby certify that on February 26, 2018, I caused the foregoing to be electronically filed with the Clerk of the Court using the CM/ECF system, which will send notification of the filing to all participants in the case who are registered CM/ECF users. I further certify that I have caused the foregoing to be mailed by First Class Mail, postage paid, to the following non-CM/ECF participants: Beverly Yadao Palacio 1130 South Flower Suite 310 Los Angeles, CA 90015 Santiago Cuellar 1709 Christian Court Weslaco, TX 78596 /s/ Andrew W. Robertson Andrew W. Robertson